Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.64 |
| ▸ | PARP11 | Q9NR21 | 3/20 | 0.64 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.41 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | S100A4 | P26447 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2616885 | 0.85 | PARP10 (0.64) | PARP10PARP11PARP1PNMTASIC3 | |
| SCHEMBL13512608 | 0.78 | PARP10 (0.64) | PARP10PARP11PARP1PNMTASIC3 | |
| SCHEMBL18281237 | 0.78 | PARP10 (0.50) | PARP10PARP11PARP1PNMTSRD5A1 | |
| SCHEMBL1002712 | 0.78 | PARP10 (1.00) | PARP10PARP11PARP1TDP2 | |
| Hydrochloric Acid SCHEMBL31432826 | 0.75 | DRD2 (0.57) | PARP10PARP11PARP1PNMTASIC3 | |
| SCHEMBL24699354 | 0.73 | PARP10 (0.76) | PARP10PARP11PARP1PNMTASIC3 | |
| SCHEMBL204100 | 0.73 | SRD5A1 (0.64) | PARP10PARP11PARP1PNMTASIC3 | |
| SCHEMBL31268305 | 0.73 | SRD5A1 (0.64) | PARP10PARP11PARP1PNMTASIC3 | |
| SCHEMBL88901 | 0.72 | PARP1 (0.59) | PARP10PARP11PARP1PNMTHTR2C | |
| SCHEMBL10815 | 0.72 | DRD2 (0.59) | PARP10PARP11PARP1PNMTASIC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | PARP10 1423/4885PARP11 1472/4885PARP1 1660/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | PARP10 273/4885PARP11 216/4885PARP1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.